Antibody-based fusion proteins to target death receptors in cancer
Cancer letters, 2013•Elsevier
Ideally, an immunotoxin should be inactive 'en route', acquire activity only after tumor cell
surface binding and have no off-target effects towards normal cells. In this respect, antibody-
based fusion proteins that exploit the tumor-selective pro-apoptotic death ligands sFasL and
sTRAIL appear promising. Soluble FasL largely lacks receptor-activating potential, whereas
sTRAIL is inactive towards normal cells. Fusion proteins in which an anti-tumor antibody
fragment (scFv) is fused to sFasL or sTRAIL prove to be essentially inactive when soluble …
surface binding and have no off-target effects towards normal cells. In this respect, antibody-
based fusion proteins that exploit the tumor-selective pro-apoptotic death ligands sFasL and
sTRAIL appear promising. Soluble FasL largely lacks receptor-activating potential, whereas
sTRAIL is inactive towards normal cells. Fusion proteins in which an anti-tumor antibody
fragment (scFv) is fused to sFasL or sTRAIL prove to be essentially inactive when soluble …
Ideally, an immunotoxin should be inactive ‘en route’, acquire activity only after tumor cell surface binding and have no off-target effects towards normal cells. In this respect, antibody-based fusion proteins that exploit the tumor-selective pro-apoptotic death ligands sFasL and sTRAIL appear promising. Soluble FasL largely lacks receptor-activating potential, whereas sTRAIL is inactive towards normal cells. Fusion proteins in which an anti-tumor antibody fragment (scFv) is fused to sFasL or sTRAIL prove to be essentially inactive when soluble, while gaining potent anti-tumor activity after selective binding to a predefined tumor-associated cell surface antigen. Importantly, off-target binding by scFv:sTRAIL to normal cells showed no signs of toxicity. In this review, we highlight the rationale and perspectives of scFv:TRAIL/scFv:sFasL based fusion proteins for cancer therapy.
Elsevier